SAB Biotherapeutics Inc (SABS) Q4 2025 Earnings Call Transcript

Why It Matters

The extended cash runway and regulatory alignment position Altimmune to advance PEMB toward potential accelerated approval, addressing a large unmet need in NASH and related liver diseases. High physician intent to prescribe could translate into significant market share if Phase III confirms efficacy and safety.

Key Takeaways

• Cash runway extends to 2028 covering Phase III NASH trial
• Phase III will enroll ~1,800 patients with AI‑assisted histology
• PEMB received FDA Breakthrough Therapy designation for NASH
• Phase II showed 7.5% weight loss and fibrosis improvements
• Physicians predict high adoption, >70% likely to prescribe

Pulse Analysis

The global non‑alcoholic steatohepatitis (NASH) market remains fragmented, with few therapies delivering both robust histologic improvement and tolerable dosing. Altimmune’s PEMB, a dual GLP‑1/glucagon receptor agonist, aims to fill this gap by targeting hepatic fat accumulation and metabolic drivers in a single molecule. The recent Breakthrough Therapy designation underscores the FDA’s recognition of its preliminary efficacy, especially given the 48‑week Phase II results that showed significant reductions in ELF scores, liver stiffness, and a sustained 7.5% weight loss—metrics that compare favorably with existing approved agents.

Altimmune’s Phase III design reflects a strategic blend of regulatory foresight and technological innovation. Enrolling roughly 1,800 patients, the trial splits a primary cohort of 990 biopsy‑confirmed F2/F3 NASH participants evenly across placebo, 1.8 mg, and 2.4 mg arms, while leveraging AI‑assisted histologic assessment to enhance endpoint precision. This approach not only aligns with FDA expectations for biopsy‑driven outcomes but also positions the study for accelerated approval pathways, should the primary endpoints of NASH resolution or fibrosis improvement be met at 52 weeks. A secondary, non‑invasive cohort will further validate biomarker trends, providing a safety net for future regulatory submissions in Europe and the UK.

Financially, Altimmune’s strengthened balance sheet—bolstered by a $75 million capital raise and an $8 million ATM facility—delivers a runway through 2028, comfortably covering the costly Phase III program and ongoing Phase II AUD and ALD studies. Coupled with physician surveys indicating over 70% likelihood to prescribe PEMB, the company is poised to capture a sizable share of the projected $30 billion NASH treatment market. Successful Phase III outcomes could also unlock cross‑indication synergies, expanding PEMB’s relevance to obesity, alcohol‑related liver disease, and broader metabolic disorders.